Product Comparison


 
Sanofi Pasteur 589-05
Glaxo Smith Kline 58160095509
Glaxo Smith Kline 58160097620
Pfizer 00005010005
Pfizer 00005010010
McKesson # 581508 1064517 1047522 944569 944570
Description Menactra® Meningitis Vaccine Meningococcal (Groups A,C,Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Preservative Free 4 mcg / 0.5 mL Injection Single Dose Vial 0.5 mL Menveo® Meningitis Vaccine Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free 10 mcg - 5 mcg / 0.5 mL Injection Single Dose Vial 0.5 mL Bexsero® Meningitis Vaccine For Individuals 10 Through 25 Years of Age Meningococcal Group B Vaccine 50 mcg - 50 mcg / 0.5 mL Injection Prefilled Syringe 10 Syringes Trumenba® Meningitis Vaccine For Individuals 10 Through 25 Years of Age Meningococcal Group B Vaccine 120 mcg / 0.5 mL Injection Prefilled Syringe 5 Syringes Trumenba® Meningitis Vaccine For Individuals 10 Through 25 Years of Age Meningococcal Group B Vaccine 120 mcg / 0.5 mL Injection Prefilled Syringe 10 Syringes
Manufacturer # 589-0558160095509581600976200000501000500005010010
Brand Menactra®Menveo®Bexsero®Trumenba®Trumenba®
Manufacturer Sanofi PasteurGlaxo Smith KlineGlaxo Smith KlinePfizerPfizer
Invoice MENACTRA VACCINE, VL 4MCG/.05ML (5/CT)MENVEO VACCINE, SDV 10-5MG/0.5ML (5/CT)BEXSERO, PFS 0.5ML (10/BX) RXTRUMENBA VACCINE, SYR 0.5ML (5/BX) 9PFIZTRUMENBA VACCINE, SYR 0.5ML (10/BX)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Alternate Manufacturer Number 34065273406535
Container Type Single Dose VialSingle Dose VialPrefilled SyringePrefilled SyringePrefilled Syringe
Country of Origin United StatesUnknownUnknownIrelandIreland
Generic Drug Code 9953928272359443741337413
Generic Drug Name Meningococcal (Groups A,C,Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Preservative FreeMeningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative FreeMeningococcal Group B VaccineMeningococcal Group B VaccineMeningococcal Group B Vaccine
NDC Number 4928105890558160095509581600976200000501000500005010010
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 days
Strength 4 mcg / 0.5 mL10 mcg - 5 mcg / 0.5 mL50 mcg - 50 mcg / 0.5 mL120 mcg / 0.5 mL120 mcg / 0.5 mL
User For Individuals 10 Through 25 Years of AgeFor Individuals 10 Through 25 Years of AgeFor Individuals 10 Through 25 Years of Age
Volume 0.5 mL0.5 mL10 Syringes5 Syringes10 Syringes
Application Meningitis VaccineMeningitis VaccineMeningitis VaccineMeningitis VaccineMeningitis Vaccine
Dosage Form InjectionInjectionInjectionInjectionInjection
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Type IntramuscularIntramuscularIntramuscularIntramuscularIntramuscular
UNSPSC Code 5120161051201610512016105120161051201610
Features and Benefits
  • Menactra is indicated for active immunization of individuals 2 through 55 years of age for the prevention of invasive meningococcal disease
  • Menactra vaccine is administered as a 0.5 mL dose by intramuscular injection
  • In children 9 through 23 months of age, Menactra is given as a 2-dose series three months apart
  • Do not administer this product intravenously or subcutaneously
  • Requires refrigeration
  • MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
  • MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
  • BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
  • BEXSERO is approved for use in individuals 10 through 25 years of age
  • BEXSERO is supplied as a 0.5 mL suspension in a glass pre-filled syringe
  • Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
  • Trumenba is a suspension for intramuscular injection in 0.5 mL single-dose prefilled syringe
  • Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
  • Trumenba is a suspension for intramuscular injection in 0.5 mL single-dose prefilled syringe